RhumbLine Advisers’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.7M | Sell |
192,706
-19,756
| -9% | -$1.43M | 0.01% | 872 |
|
|
2026
Q1 | $14.5M | Buy |
212,462
+4,512
| +2% | +$320K | 0.01% | 887 |
|
|
2025
Q4 | $15.8M | Buy |
207,950
+94,046
| +83% | +$6.83M | 0.01% | 844 |
|
|
2025
Q3 | $6.99M | Sell |
113,904
-4,635
| -4% | -$241K | 0.01% | 1259 |
|
|
2025
Q2 | $5.79M | Buy |
118,539
+6,726
| +6% | +$319K | 0.01% | 1332 |
|
|
2025
Q1 | $5.7M | Sell |
111,813
-588
| -0.5% | -$29.3K | 0.01% | 1290 |
|
|
2024
Q4 | $5.07M | Buy |
112,401
+1,630
| +1% | +$69.8K | ﹤0.01% | 1416 |
|
|
2024
Q3 | $4.11M | Sell |
110,771
-5,625
| -5% | -$188K | ﹤0.01% | 1533 |
|
|
2024
Q2 | $3.56M | Buy |
116,396
+7,314
| +7% | +$237K | ﹤0.01% | 1586 |
|
|
2024
Q1 | $3.17M | Buy |
109,082
+2,896
| +3% | +$81.1K | ﹤0.01% | 1665 |
|
|
2023
Q4 | $2.93M | Sell |
106,186
-818
| -0.8% | -$18.7K | ﹤0.01% | 1707 |
|
|
2023
Q3 | $2.4M | Buy |
107,004
+1,322
| +1% | +$49.2K | ﹤0.01% | 1771 |
|
|
2023
Q2 | $4.3M | Buy |
105,682
+2,312
| +2% | +$113K | ﹤0.01% | 1467 |
|
|
2023
Q1 | $5.01M | Buy |
103,370
+1,736
| +2% | +$79.3K | 0.01% | 1313 |
|
|
2022
Q4 | $3.88M | Buy |
101,634
+3,015
| +3% | +$125K | 0.01% | 1422 |
|
|
2022
Q3 | $4.95M | Buy |
98,619
+9,000
| +10% | +$441K | 0.01% | 1234 |
|
|
2022
Q2 | $3.59M | Buy |
89,619
+15,536
| +21% | +$545K | 0.01% | 1446 |
|
|
2022
Q1 | $2.76M | Sell |
74,083
-72
| -0.1% | -$2.77K | ﹤0.01% | 1644 |
|
|
2021
Q4 | $2.95M | Sell |
74,155
-886
| -1% | -$33.9K | ﹤0.01% | 1674 |
|
|
2021
Q3 | $2.79M | Sell |
75,041
-809
| -1% | -$33.2K | ﹤0.01% | 1704 |
|
|
2021
Q2 | $3.21M | Buy |
75,850
+3,864
| +5% | +$166K | ﹤0.01% | 1687 |
|
|
2021
Q1 | $3.41M | Sell |
71,986
-8,590
| -11% | -$510K | ﹤0.01% | 1626 |
|
|
2020
Q4 | $4.92M | Buy |
80,576
+2,258
| +3% | +$133K | 0.01% | 1361 |
|
|
2020
Q3 | $3.66M | Sell |
78,318
-21,052
| -21% | -$1.04M | 0.01% | 1349 |
|
|
2020
Q2 | $5.04M | Buy |
99,370
+10,316
| +12% | +$507K | 0.01% | 1209 |
|
|
2020
Q1 | $3.97M | Buy |
89,054
+1,091
| +1% | +$54.9K | 0.01% | 1167 |
|
|
2019
Q4 | $4.22M | Buy |
87,963
+7,141
| +9% | +$303K | 0.01% | 1354 |
|
|
2019
Q3 | $2.73M | Buy |
80,822
+1,057
| +1% | +$46K | 0.01% | 1558 |
|
|
2019
Q2 | $3.59M | Buy |
79,765
+11,762
| +17% | +$464K | 0.01% | 1385 |
|
|
2019
Q1 | $2.56M | Buy |
68,003
+7,624
| +13% | +$256K | 0.01% | 1568 |
|
|
2018
Q4 | $2.07M | Buy |
60,379
+19,444
| +47% | +$699K | ﹤0.01% | 1621 |
|
|
2018
Q3 | $1.92M | Sell |
40,935
-2,761
| -6% | -$114K | ﹤0.01% | 1684 |
|
|
2018
Q2 | $1.47M | Buy |
43,696
+5,503
| +14% | +$172K | ﹤0.01% | 1834 |
|
|
2018
Q1 | $1.03M | Sell |
38,193
-1,003
| -3% | -$25.4K | ﹤0.01% | 1928 |
|
|
2017
Q4 | $654K | Sell |
39,196
-2,907
| -7% | -$49.2K | ﹤0.01% | 2125 |
|
|
2017
Q3 | $842K | Buy |
42,103
+3,335
| +9% | +$65.3K | ﹤0.01% | 2057 |
|
|
2017
Q2 | $711K | Sell |
38,768
-3,525
| -8% | -$47.5K | ﹤0.01% | 2136 |
|
|
2017
Q1 | $416K | Buy |
42,293
+1,173
| +3% | +$14.2K | ﹤0.01% | 2333 |
|
|
2016
Q4 | $449K | Sell |
41,120
-972
| -2% | -$10.2K | ﹤0.01% | 2281 |
|
|
2016
Q3 | $590K | Sell |
42,092
-7,243
| -15% | -$58.9K | ﹤0.01% | 2104 |
|
|
2016
Q2 | $346K | Buy |
49,335
+15,348
| +45% | +$113K | ﹤0.01% | 2435 |
|
|
2016
Q1 | $219K | Buy |
33,987
+740
| +2% | +$12.8K | ﹤0.01% | 2697 |
|
|
2015
Q4 | $1.08M | Buy |
33,247
+2,485
| +8% | +$73.1K | ﹤0.01% | 1754 |
|
|
2015
Q3 | $821K | Sell |
30,762
-96
| -0.3% | -$4.11K | ﹤0.01% | 1893 |
|
|
2015
Q2 | $1.49M | Buy |
30,858
+5,110
| +20% | +$298K | ﹤0.01% | 1614 |
|
|
2015
Q1 | $1.57M | Buy |
25,748
+4,505
| +21% | +$275K | ﹤0.01% | 1557 |
|
|
2014
Q4 | $1.1M | Buy |
21,243
+2,000
| +10% | +$88K | ﹤0.01% | 1738 |
|
|
2014
Q3 | $847K | Buy |
19,243
+130
| +0.7% | +$4.07K | ﹤0.01% | 1867 |
|
|
2014
Q2 | $500K | Buy |
+19,113
| New | +$409K | ﹤0.01% | 2271 |
|
Other funds holding PTCT
RI
JT
RhumbLine Advisers's PTCT Position: Q2 2026 in Review
RhumbLine Advisers reduced its PTC Therapeutics (PTCT) stake by 9.3% in Q2 2026, selling an estimated $1.43M and leaving 192,706 shares worth $15.7M. The position accounts for 0.01% of the portfolio, ranked #872.
RhumbLine Advisers first reported a position in PTCT in Q2 2014 and has held it in 49 quarters since. The position peaked at $15.8M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- RhumbLine Advisers held 192,706 shares of PTC Therapeutics worth $15.7M as of Q2 2026.
- RhumbLine Advisers sold 19,756 PTC Therapeutics shares in Q2 2026, an estimated $1.43M.
- PTC Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #872 holding.
- RhumbLine Advisers first reported a position in PTC Therapeutics in Q2 2014 and has held it in 49 quarters since.
- RhumbLine Advisers's PTC Therapeutics position peaked at $15.8M in Q4 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.